Wellnow Urgent Care and Research
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scarberry, Stephanie
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
Pollock, Sarah
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Recruiting
3
200
Europe, US
Rimegepant (PF-07899801)
Pfizer
Acute Treatment of Migraine
06/27
06/27
Burns, Gena
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24
NCT05672875: Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Terminated
N/A
343
US
Anthrax LF Dx System
SRI International, Department of Health and Human Services
Anthrax
04/23
04/23
Cordero, Abner
NCT05461573: Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Active, not recruiting
3
1009
US
Drospirenone, LPRI-CF113
Insud Pharma, Chemo Research
Contraception, Change in Bone Mineral Density
05/24
05/25
NCT05672875: Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Terminated
N/A
343
US
Anthrax LF Dx System
SRI International, Department of Health and Human Services
Anthrax
04/23
04/23

Download Options